{"url_path":"/sec/rmtg/10-k/2026/item-11","section_key":"item-11","section_title":"Item 11 **","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","accession_number":"0001213900-26-056841","cik":"0001760026","ticker":"RMTG","issuer_name":"Regenerative Medical Technology Group Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","primary_entity_key":"0001760026","primary_entity_name":"Regenerative Medical Technology Group Inc."},"word_count":529,"has_tables":true,"body_markdown":"**ITEM 11.**\n**EXECUTIVE COMPENSATION.**\n\n \n\nThe following summary compensation table sets\nforth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the years ended December 31, 2025,\nand 2024.\n\n \n\n**EXECUTIVE OFFICER COMPENSATION TABLE**\n\n \n\nName and Principal Position\n \nYear\n \n \nSalary\n($)\n \n \nBonus\n($)\n \n \nStock\nAwards\n($)\n \n \nOption\nAwards\n($)\n \n \nNon-Equity\nIncentive Plan\nCompensation\n($)\n \n \nNon-Qualified\nDeferred\nCompensation\nEarnings\n($)\n \n \nAll Other\nCompensation\n($)\n \n \nTotal\n($)\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nDavid Christensen\n \n \n2025\n \n \n \n90,000\n \n \n \n          \n \n \n \n            -\n \n \n \n               \n \n \n \n               \n \n \n \n                 \n \n \n \n                    \n \n \n \n90,000\n \n\nPresident, Chief Executive\nOfficer (Principal\nExecutive\nOfficer), Chief\n\nFinancial Officer\n\n(Principal Accounting\nOfficer and Principal\nFinancial Officer),\nSecretary And\nDirector\n \n \n2024\n \n \n \n90,000\n \n \n \n \n \n \n \n-\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n90,000\n \n\n \n\n**Outstanding Equity Awards at the End of the\nFiscal Year**\n\n \n\nWe do not have any equity compensation plans and therefore no equity\nawards are outstanding as of December 31, 2025.\n\n** **\n\nNone of the members of the board of directors\nof the Company were compensated for services in such capacity.\n\n \n\n**Bonuses and Deferred Compensation**\n\n \n\nWe do not have any bonus, deferred compensation\nor retirement plan. All decisions regarding compensation are determined by our board of directors.\n\n \n\n31\n\n \n\n**Payment of Post-Termination Compensation**\n\n \n\nWe do not have change-in-control agreements with\nour director or executive officer, and we are not obligated to pay severance or other enhanced benefits to our executive officer upon\ntermination of her employment.\n\n \n\n**Employment Agreements**\n\n \n\nOn August 18, 2021, the Company entered into a\nthree-year Consulting Agreement with ETC (Enterprise Technology Consulting), a company owned by David Christensen, the Company’s\nChief Executive Officer. Under the terms of the agreement, ETC was compensated at an annual rate of $90,000, payable monthly. In addition,\nthe agreement provided for the issuance of 896 shares of Series DD Preferred Stock of the Company, with 448 shares issued on August 18,\n2021, and the remaining 448 shares issued on February 18, 2022.\n\n \n\nThe original Consulting Agreement expired in August\n2024. Following the expiration, the Company has continued to compensate ETC at the same annual rate of $90,000, payable monthly, on a\nmonth-to-month basis while finalizing terms for a new agreement.\n\n \n\nThe Company intends to enter into a new formal\nconsulting agreement with ETC during 2026 to continue these services. This new agreement is expected to maintain similar compensation\nterms, reflecting the ongoing essential role of Mr. Christensen’s leadership and strategic oversight in the Company’s operations,\ninternational expansion, and execution of its regenerative medicine business plan. Any new agreement will be subject to approval by the\nBoard of Directors and will be disclosed in accordance with applicable SEC reporting requirements.\n\n \n\nAs of the date of this report, no other employment\nagreements or material compensatory arrangements with executive officers or key personnel have been entered into or modified that require\ndisclosure.\n\n \n\n**Board of Directors**\n\n \n\nOur directors hold office until the next annual\nmeeting of shareholders and until their successors have been duly elected and qualified. Our officers are elected by and serve at the\ndiscretion of the board of directors.\n\n \n\n**Securities Authorized for Issuance Under Equity\nCompensation Plans**\n\n \n\nAs of December 31, 2025, we did not have any securities\nauthorized for issuance under any equity compensation plans.\n\n  \n\n**Compensation of Directors**\n\n \n\nNo director received compensation for his services\nduring the year ended December 31, 2025.\n\n \n\n32"}